Showing results (481-490 of 502) with videos related to
Sort By:
Pageof 51
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2022
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2017
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)Dara L Aisner, Lynette M Sholl, Lynne D Berry, et al.Cancer|October 25, 2019
Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trialsDylan J Martini, Meredith R Kline, Yuan Liu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2020
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 PandemicAnne-Marie C Dingemans, Ross A Soo, Abdul Rahman Jazieh, et al.The Oncologist|March 13, 2020
Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with ImmunotherapyMehmet Asim Bilen, Dylan J Martini, Yuan Liu, et al.Nature Medicine|November 9, 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialPatrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2015
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400Roy S Herbst, David R Gandara, Fred R Hirsch, et al.Future Oncology (London, England)|November 12, 2024
Plain language summary: tarlatamab for patients with previously treated small cell lung cancerMyung-Ju Ahn, Byoung Chul Cho, Enriqueta Felip, et al.Pageof 51